Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
A new Supernus Pharmaceuticals medical device that continuously administers an old Parkinson’s disease drug is now FDA approved, giving patients another way to manage the motor control symptoms ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results